AMAKA ANYAOHA: Open Payments
NPI 1043439813 · EL SEGUNDO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,510 in 28 payments from 13 companies in 2025. Trend: 2023 $97 · 2024 $3,051 · 2025 $2,510
Food & beverage: $2,510
| Company | Payments | Amount |
|---|---|---|
| Janssen Pharmaceuticals, Inc | 5 | $642 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $399 |
| AstraZeneca Pharmaceuticals LP | 3 | $328 |
| ABBVIE INC. | 4 | $271 |
| Otsuka America Pharmaceutical, Inc. | 5 | $135 |
| Alkermes, Inc. | 1 | $123 |
| ViiV Healthcare Company | 1 | $122 |
| Teva Pharmaceuticals USA, Inc. | 1 | $121 |
| Biogen, Inc. | 1 | $114 |
| E.R. Squibb & Sons, L.L.C. | 1 | $112 |
Products named: INVEGA SUSTENNA, CAPLYTA, VRAYLAR, LYBALVI, DATROWAY, APRETUDE, UZEDY, BREZTRI.
Industry payments across CA — which companies pay providers there.
